Literature DB >> 26147013

Sebaceous Carcinoma of the Ocular Region: The 2014 Professor Winifred Mao Lecture.

Jerry A Shields1, Jarin Saktanasate, Sara E Lally, Jacqueline R Carrasco, Carol L Shields.   

Abstract

Sebaceous carcinoma is a malignancy arising in the periocular region that can lead to blindness and tumor-related metastases. This study is a review of published literature and personal experience. This malignancy can arise from the sebaceous units in the tarsus (meibomian glands), in association with the cilia (Zeis glands), in the brow, and in the caruncle. There is a tendency for diffuse intraepithelial growth (pagetoid spread) that can be clinically invisible. Detection before lymph node metastasis is critical. This malignancy often masquerades as chronic unilateral conjunctivitis or blepharitis, typically in older patients. Management includes a 2-step approach with step 1 focused on eyelid and conjunctival map biopsies to determine the full extent of solid deep tumor and pagetoid spread. After complete review of all biopsies, step 2 is performed using local resection for all deep tumor, cryotherapy to pagetoid disease, and reconstruction. In most cases, the posterior lamella of eyelid is sacrificed with tumor removal, whereas the anterior lamella of the eyelid can be saved. After removal and cryotherapy, immediate reconstruction, using clean instruments, with buccal membrane graft for the posterior lamella and skin flap for the anterior lamella, is developed. For persistent or recurrent pagetoid disease, cryotherapy, topical mitomycin C, or plaque radiotherapy is provided. Exenteration is sometimes necessary. Sebaceous carcinoma, if detected early, can be managed with carefully planned map biopsy to determine tumor extent, followed by local resection, cryotherapy, and eyelid reconstruction. Orbital exenteration is occasionally necessary.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26147013     DOI: 10.1097/APO.0000000000000105

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN: 2162-0989


  8 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

3.  High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.

Authors:  Thomas J Kandl; Oded Sagiv; Jonathan L Curry; Jing Ning; Junsheng Ma; Courtney W Hudgens; John Van Arnam; Jennifer A Wargo; Bita Esmaeli; Michael T Tetzlaff
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

Review 4.  Updates on the clinical diagnosis and management of ocular sebaceous carcinoma: a brief review of the literature.

Authors:  Yangfan Xu; Fang Li; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2018-06-27       Impact factor: 4.147

5.  Clinicopathological Analysis and Surgical Outcome of Eyelid Malignancies: A Study of 332 Cases.

Authors:  Syeed Mehbub Ul Kadir; Mukti Rani Mitra; Riffat Rashid; Murtuza Nuruddin; Md Kamrul Hassan Khan; Golam Haider; Mst Sayedatun Nessa
Journal:  J Skin Cancer       Date:  2022-02-18

6.  Left Buttock Sebaceus Carcinoma: A Case Report and Review of the Literature.

Authors:  Răzvan Mercuţ; Mihaela Ionescu; Cristiana Simionescu; Vlad Pîrvănescu; Maria Filoftea Mercuţ; Alexandru Gogănău; Marius Eugen Ciurea
Journal:  Curr Health Sci J       Date:  2021-12-31

7.  Commentary: Cryotherapy and the sebaceous glands.

Authors:  Aditi Mehta; Manpreet Kaur; Manpreet Singh; Pankaj Gupta
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 1.848

8.  The effect of direct cell injury inflicted by cryotherapy on eyelid sebaceous gland carcinoma cells: An ex-vivo experimental study.

Authors:  Md Shahid Alam; Prabrisha Banerjee; Subramanian Krishnakumar
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.